From the Departments of Internal Medicine and Molecular Physiology & Biophysics, Cardiovascular Research Center, Carver College of Medicine, University of Iowa, Iowa City (M.E.A); Cedars-Sinai Heart Institute, Los Angeles, CA (J.G.); Department of Physiology and Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.R.H.); INSERM UMR 910, Génétique médicale et génomique fonctionnelle, Université Aix Marseille, Team Physiopathology of Cardiac Development, Faculté de Medecine La Timone, Marseille, France (M.P.); and Biology Department, Integrated Regenerative Research Institute, San Diego State University, CA (M.A.S.).
Circ Res. 2014 Jul 18;115(3):335-8. doi: 10.1161/CIRCRESAHA.114.304616. Epub 2014 Jun 16.
Recently a preclinical report assessed the efficacy, safety, and feasibility of using human embryonic stem cells to regenerate infarcted myocardium in a non-human primate model. This commentary evaluates that study by pointing out key weaknesses, offering an alternative perspective, and summarizing major unresolved issues. Our conclusion is that significant challenges remain before human embryonic stem cells are ready for use in clinical trials.
最近有一份临床前报告评估了使用人类胚胎干细胞在非人类灵长类动物模型中再生梗死心肌的疗效、安全性和可行性。本评论通过指出关键弱点、提供替代观点和总结主要未解决问题来评估该研究。我们的结论是，在人类胚胎干细胞准备用于临床试验之前，仍然存在重大挑战。
